Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04929392
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:22.092163+00:00
Published At
2025-09-04T00:00:00+00:00
Record Updated At
2025-09-04
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-09-04"
protocolSection.identificationModule.nctId
"NCT04929392"
protocolSection.identificationModule.officialTitle
"A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.